Cargando…

The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study

The COVID-19 pandemic caused unprecedented disruption in health service delivery, globally. This study sought to provide evidence on the impact of the pandemic on vaccine coverage in Kilifi County, Kenya. We conducted a vaccine coverage survey between April and June 2021 within the Kilifi Health and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucinde, R.K., Karia, B., Ouma, N., Amadi, D., Nyundo, C., Mataza, C., Nyaguara, A., Scott, J.A.G., Gallagher, K.E., Kagucia, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622384/
https://www.ncbi.nlm.nih.gov/pubmed/36543684
http://dx.doi.org/10.1016/j.vaccine.2022.10.074
_version_ 1784821755734392832
author Lucinde, R.K.
Karia, B.
Ouma, N.
Amadi, D.
Nyundo, C.
Mataza, C.
Nyaguara, A.
Scott, J.A.G.
Gallagher, K.E.
Kagucia, E.
author_facet Lucinde, R.K.
Karia, B.
Ouma, N.
Amadi, D.
Nyundo, C.
Mataza, C.
Nyaguara, A.
Scott, J.A.G.
Gallagher, K.E.
Kagucia, E.
author_sort Lucinde, R.K.
collection PubMed
description The COVID-19 pandemic caused unprecedented disruption in health service delivery, globally. This study sought to provide evidence on the impact of the pandemic on vaccine coverage in Kilifi County, Kenya. We conducted a vaccine coverage survey between April and June 2021 within the Kilifi Health and Demographic Surveillance System (KHDSS). Simple random sampling was used to identify 1500 children aged 6 weeks–59 months. Participants were grouped into three retrospective cohorts based on when they became age-eligible for vaccination: before the pandemic, during the first year, or during the second year of the pandemic. Survival analysis with Cox regression was used to evaluate the association between the time-period at which participants became age-eligible for vaccination and the rate of vaccination within a month of age-eligibility for the third dose of pentavalent vaccine (Pentavalent-3) and within three months of age-eligibility for the first dose of Measles vaccine (MCV-1). A total of 1,341 participants were included in the survey. Compared to the pre-COVID-19 baseline period, the rate of vaccination within a month of age-eligibility for Pentavalent-3 was not significantly different in the first year of the pandemic (adjusted hazard ratio [aHR] 1.03, 95 % confidence interval [CI] 0.90–1.18) and was significantly higher during the second year of the pandemic (aHR 1.33, 95 % CI 1.07–1.65). The rate of vaccination with MCV-1 within three months of age-eligibility was not significantly different among those age-eligible for vaccination during the first year of the pandemic (aHR 1.04, 95 % CI 0.88–1.21) and was 35 % higher during the second year of the pandemic (95 % CI 1.11–1.64), compared to those age-eligible pre-COVID-19. After adjusting for known determinants of vaccination, the COVID-19 pandemic did not adversely affect the rate of vaccination within the KHDSS.
format Online
Article
Text
id pubmed-9622384
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-96223842022-11-01 The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study Lucinde, R.K. Karia, B. Ouma, N. Amadi, D. Nyundo, C. Mataza, C. Nyaguara, A. Scott, J.A.G. Gallagher, K.E. Kagucia, E. Vaccine Article The COVID-19 pandemic caused unprecedented disruption in health service delivery, globally. This study sought to provide evidence on the impact of the pandemic on vaccine coverage in Kilifi County, Kenya. We conducted a vaccine coverage survey between April and June 2021 within the Kilifi Health and Demographic Surveillance System (KHDSS). Simple random sampling was used to identify 1500 children aged 6 weeks–59 months. Participants were grouped into three retrospective cohorts based on when they became age-eligible for vaccination: before the pandemic, during the first year, or during the second year of the pandemic. Survival analysis with Cox regression was used to evaluate the association between the time-period at which participants became age-eligible for vaccination and the rate of vaccination within a month of age-eligibility for the third dose of pentavalent vaccine (Pentavalent-3) and within three months of age-eligibility for the first dose of Measles vaccine (MCV-1). A total of 1,341 participants were included in the survey. Compared to the pre-COVID-19 baseline period, the rate of vaccination within a month of age-eligibility for Pentavalent-3 was not significantly different in the first year of the pandemic (adjusted hazard ratio [aHR] 1.03, 95 % confidence interval [CI] 0.90–1.18) and was significantly higher during the second year of the pandemic (aHR 1.33, 95 % CI 1.07–1.65). The rate of vaccination with MCV-1 within three months of age-eligibility was not significantly different among those age-eligible for vaccination during the first year of the pandemic (aHR 1.04, 95 % CI 0.88–1.21) and was 35 % higher during the second year of the pandemic (95 % CI 1.11–1.64), compared to those age-eligible pre-COVID-19. After adjusting for known determinants of vaccination, the COVID-19 pandemic did not adversely affect the rate of vaccination within the KHDSS. The Authors. Published by Elsevier Ltd. 2023-01-16 2022-11-01 /pmc/articles/PMC9622384/ /pubmed/36543684 http://dx.doi.org/10.1016/j.vaccine.2022.10.074 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Lucinde, R.K.
Karia, B.
Ouma, N.
Amadi, D.
Nyundo, C.
Mataza, C.
Nyaguara, A.
Scott, J.A.G.
Gallagher, K.E.
Kagucia, E.
The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study
title The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study
title_full The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study
title_fullStr The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study
title_full_unstemmed The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study
title_short The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study
title_sort impact of the covid-19 pandemic on vaccine coverage in kilifi, kenya: a retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622384/
https://www.ncbi.nlm.nih.gov/pubmed/36543684
http://dx.doi.org/10.1016/j.vaccine.2022.10.074
work_keys_str_mv AT lucinderk theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT kariab theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT ouman theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT amadid theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT nyundoc theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT matazac theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT nyaguaraa theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT scottjag theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT gallagherke theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT kaguciae theimpactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT lucinderk impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT kariab impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT ouman impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT amadid impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT nyundoc impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT matazac impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT nyaguaraa impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT scottjag impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT gallagherke impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy
AT kaguciae impactofthecovid19pandemiconvaccinecoverageinkilifikenyaaretrospectivecohortstudy